Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK).

Parisa Momtaz,Catherine Anne O'Connor,Joanne F. Chou,Marinela Capanu,Kenneth H. Yu,Anna M. Varghese,Wungki Park,Alice Zervoudakis,Jia Li,Geoffrey Y. Ku,Diane Lauren Reidy,Marina Shcherba,James J. Harding,Zoe Goldberg,Ghassan K. Abou-Alfa,Zsofia K. Stadler,Erin E. Salo-Mullen,Eileen M. O’Reilly

Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK).

2020

Parisa Momtaz
Catherine Anne O'Connor
Joanne F. Chou
Marinela Capanu
Kenneth H. Yu
Anna M. Varghese
Wungki Park
Alice Zervoudakis
Jia Li
Geoffrey Y. Ku
Diane Lauren Reidy
Marina Shcherba
James J. Harding
Zoe Goldberg
Ghassan K. Abou-Alfa
Zsofia K. Stadler
Erin E. Salo-Mullen
Eileen M. O’Reilly

708Background: Given encouraging responses of platinum agents and poly-ADP ribose polymerase inhibitors (PARPi) in BRCA mutated (mut) PDAC, we sought to identify patients (pts) with BRCA mut PDAC t...

Keywords:

pancreatic ductal adenocarcinoma
Cancer
Cohort
Internal medicine
Oncology
Medicine
Pathology
Platinum Agents

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations